Abstract
The effect of syngeneic anti-idiotypic (anti-id) antibodies on the biodistribution of three murine monoclonal antibodies (mAb) against human tumour-associated antigens, and also on that of their fragments, has been examined in mice using, as a model system, purified anti-id mAb against three different target mAb. With the IgG2b mAb NCRC-2, pretreatment of mice 24 h previously with its IgG1 anti-id mAb NCRC-60 caused clearance of subsequently administered NCRC-2. With the univalent Fab/c fragment of NCRC-2 there was little effect, even with anti-id to Fab/c pretreatment ratios of 20∶1, although immune complexes were present in the circulation. With Fab of NCRC-2, anti-id mAb prolonged blood survival by reducing renal clearance, immune complexes surviving in the circulation. With the IgG1 mAb NCRC-23, immune complexes formed in vivo with the IgG2b anti-id mAb NCRC-59, but with only little hepatic clearance. With the Fab and F(ab′)2 fragments of NCRC-23, blood survival was increased in mice pretreated with anti-id mAb, and with Fab this was clearly due to reduced renal clearance. The third mAb, the IgG3 NCRC-48, formed complexes with its IgG2a anti-id mAb NCRC-62, but these survived in the circulation with no accelerated clearance of the target mAb. These results are different from those previously seen with endogenous anti-id responses. They indicate the diversity of effects that anti-id mAb can have on the biodistribution of their target mAb, and emphasise the difficulty of using such anti-id mAb to modulate the pharmacokinetics of target mAb.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- mAb:
-
monoclonal antibody
- anti-id:
-
anti-idiotypic
- PBS:
-
phosphate-buffered saline, pH 7.2
- T:B:
-
tumour to blood ratio
- AUC:
-
area under curve of plot of surviving radiolabel against time
References
Azuma J, Kurimoto T, Tsuji S, Mochizuki N, Funjinaga S, Matsumoto Y, Masuho Y (1991) Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity. J Immunother 10:278–285
Brown PS, Parenteau GL, Dirbas FM, Garsia RJ, Goldman CK, Bukowski MA, Junghans RP, Queen C, Hakimi J, Benjamin WR, Clark RE, Waldman TA (1991) Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 88:2663–2667
Chanh TC, Siwak EB, Hewetson JF (1991) Contemporary issues in toxicology. Anti-idiotype-based vaccines against biological toxins. Toxicol Appl Pharmacol 108:183–193
Demignot S, Pimm MV, Baldwin RW (1990) Comparison of biodistribution of 791T/36 monoclonal antibody and its Fab/c fragment in BALB/c mice and nude mice bearing human tumour xenografts. Cancer Res 50:2936–2942
Demignot S, Pimm MV, Thorpe SR, Baldwin RW (1991) Differences between the catabolism and tumour distribution of intact monoclonal antibody (791T/36) and its Fab/c fragment in mice with tumour xenografts revealed by the use of a residualising radiolabel (dilactitol-125I-tyramine) and autoradiography. Cancer Immunol Immunother 33:359–366
Dillman RO (1990) Human antimouse and antiglobulin responses to monoclonal antibodies. Antibody Immunoconj Radiopharm 3:1–15
Doran M, Durrant LG, Robins RA, Austin EB, Baldwin RW (1990) A syngeneic anti-idiotypic antibody to an antitumour antibody which induces cellular and humoral antitumour responses. Br J Cancer 62:533
Embleton MJ, Gunn B, Byers VS, Baldwin RW (1981) Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line. Br J Cancer 43:582–587
Fraker PJ, Speck JC (1978) Protein and cell membrane iodination with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3 α,6 α-diphenylglycoluril. Biochem Biophys Res Commun 80:849–857
Goldenberg DM, Sharkey RM, Ford E (1987) Anti-antibody enhancement of iodine-131 anti-CEA radioimmunodetection in experimental and clinical studies. J Nucl Med 28:1604–1610
Hird V, Verhoeyen M, Badley RA, Price D, Snook D, Kosmas C, Gooden C, Bamias A, Meares C, Lavender JP, Epenetos AA (1991) Tumour localization with a radioactively labelled reshaped human monoclonal antibody. Br J Cancer 64:911–914
Khazaeli MB, Saleh MN, Liu TP, Meredith RF, Wheeler RH, Baker TS, King D, Secher D, Allen L, Rogers K, Colcher D, Schlom J, Shochat D, Lobuglio AF (1991) Pharmacokinetics and immune response of131I-chimeric mouse/human B72.3 (human γ4) monoclonal antibody in humans. Cancer Res 51:5461–5466
Meredith RF, Lobuglio AF, Plott WE, Orr RA, Brezovich IA, Russell CD, Harvey EB, Yester MV, Wagner AJ, Spencer SA, Wheeler RH, Saleh MN, Rogers KJ, Polansky A, Salter MM, Khazaeli MB (1991) Pharmacokinetics, immune response and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,K 17-1A monoclonal antibody. J Nucl Med 32:1162–1168
Neuberger MS, Rajewsky K (1981) Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol 11:1012–1016
Pimm MV, Baldwin RW (1990) Syngeneic anti-idiotypic antibody prevents localisation of a murine monoclonal antibody in human tumour xenografts. Eur J Cancer 26:567–568
Pimm MV, Gribben SJ (1992) Evaluation of monoclonal anti-idiotypic antibodies as clearing antibodies for enhancement of target localisation by tumour-specific monoclonal antibodies: diversity of effects in nude mice with human tumour xenografts. Eur J Nucl Med 19:436–440
Pimm MV, Perkins AC, Baldwin RW (1986) Labelling of monoclonal antibody with metallic radionuclides: preparation of antibody-DTPA conjugates from DTPA anhydride in organic solvent. IRCS Med Sci 14:104–105
Pimm MV, Durrant LG, Baldwin RW (1989) The influence of syngeneic anti-idiotypic antibody on the biodistribution of an anti-tumour monoclonal antibody in BALB/c mice. Int J Cancer 43:147–151
Pimm MV, Gunn B, Lord JM, Baldwin RW (1990) The influence of anti-(ricin toxin A chain) monoclonal antibodies on the pharmacokinetics of ricin toxin A chain and recombinant ricin A chain in mice. Cancer Immunol Immunother 32:235–240
Price MR, Edwards S, Jacobs E, Pawluczyk IZA, Byers VS, Baldwin RW (1987) Mapping of monoclonal antibody-defined epitopes associated with carcinoembryonic antigen, CEA. Cancer Immunol Immunother 25:10–15
Price MR, Sekowski M, Tendler SJB (1991) Purification of anti-epithelial mucin monoclonal antibodies by epitope affinity chromatography. J Immunol Methods 139:83–90
Ravetch JV, Anderson NCL (1990) FcγR family: proteins, transcripts and genes. In: Metzger H (ed) Fc receptors and the action of antibodies. American Society for Microbiology, Washington DC, p 211
Rowland M, Tozer TN (1989) Clinical pharmacokinetics, 2nd edn. Lea & Fibiger, Philadelphia, p 459
Steis RG, Carrasquillo JA, McCabe R, Bookman MA, Reynolds JC, Larson SM, Smith JW, Clark JW, Dailey V, Vecchio SD, Shuke N, Pinsky CM, Urba WJ, Haspel M, Perentesis P, Paris B, Longo DL, Hanna MG Jr (1990) Toxicity, immunogenicity and tumour radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Oncol 8:476–490
Stewart JSW, Sivolapenko GB, Hird V, Davies KAA, Walport M, Ritter MA, Epenetos AA (1990) Clearance of131I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody. Cancer Res 50:563–567
Van Kroonenburgh MJPG, Pauwels EKJ (1988) Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl Med Commun 9:919–930
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pimm, M.V., Demignot, S. & Gribben, S.J. Influence of syngeneic monoclonal anti-idiotypic antibodies to murine monoclonal antibodies against tumour-associated antigens on the biodistribution of their target antibodies and their fragments. J Cancer Res Clin Oncol 119, 408–414 (1993). https://doi.org/10.1007/BF01218422
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01218422